Preliminary Results of a Phase II Study of Single Agent BAY 80-6946, a Novel PI3K Inhibitor, in Patients with Relapsed/Refractory, Indolent or Aggressive Lymphoma

Kim Linton; Martin Dreyling; Franck Morschhauser; Dominique Bron; Krimo Bouabdallah; Umberto Vitolo; Eric Van den Neste; Silvia Mappa; Marius Giurescu; Barrett H. Childs; Pier Luigi Zinzani

Preliminary Results of a Phase II Study of Single Agent BAY 80-6946, a Novel PI3K Inhibitor, in Patients with Relapsed/Refractory, Indolent or Aggressive Lymphoma

Kim Linton, Martin Dreyling, Franck Morschhauser, Dominique Bron, Krimo Bouabdallah, Umberto Vitolo, Eric Van den Neste, Silvia Mappa, Marius Giurescu, Barrett H. Childs, Pier Luigi Zinzani

Research output: Contribution to conference › Poster

Original language	English
Publication status	Published - Dec 2013
Event	American Society of Hematology Annual Conference - New Orleans Duration: 1 Jan 1824 → …

Conference

Conference	American Society of Hematology Annual Conference
City	New Orleans
Period	1/01/24 → …

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Linton, K., Dreyling, M., Morschhauser, F., Bron, D., Bouabdallah, K., Vitolo, U., Neste, E. V. D., Mappa, S., Giurescu, M., Childs, B. H., & Zinzani, P. L. (2013). Preliminary Results of a Phase II Study of Single Agent BAY 80-6946, a Novel PI3K Inhibitor, in Patients with Relapsed/Refractory, Indolent or Aggressive Lymphoma. Poster session presented at American Society of Hematology Annual Conference, New Orleans.

@conference{7575d7f24cf641fe937c4c743b46fe71,

title = "Preliminary Results of a Phase II Study of Single Agent BAY 80-6946, a Novel PI3K Inhibitor, in Patients with Relapsed/Refractory, Indolent or Aggressive Lymphoma",

author = "Kim Linton and Martin Dreyling and Franck Morschhauser and Dominique Bron and Krimo Bouabdallah and Umberto Vitolo and Neste, {Eric Van den} and Silvia Mappa and Marius Giurescu and Childs, {Barrett H.} and Zinzani, {Pier Luigi}",

year = "2013",

month = dec,

language = "English",

note = "American Society of Hematology Annual Conference ; Conference date: 01-01-1824",

}

Linton, K, Dreyling, M, Morschhauser, F, Bron, D, Bouabdallah, K, Vitolo, U, Neste, EVD, Mappa, S, Giurescu, M, Childs, BH & Zinzani, PL 2013, 'Preliminary Results of a Phase II Study of Single Agent BAY 80-6946, a Novel PI3K Inhibitor, in Patients with Relapsed/Refractory, Indolent or Aggressive Lymphoma', American Society of Hematology Annual Conference, New Orleans, 1/01/24.

Preliminary Results of a Phase II Study of Single Agent BAY 80-6946, a Novel PI3K Inhibitor, in Patients with Relapsed/Refractory, Indolent or Aggressive Lymphoma. / Linton, Kim; Dreyling, Martin; Morschhauser, Franck et al.
2013. Poster session presented at American Society of Hematology Annual Conference, New Orleans.

Research output: Contribution to conference › Poster

TY - CONF

T1 - Preliminary Results of a Phase II Study of Single Agent BAY 80-6946, a Novel PI3K Inhibitor, in Patients with Relapsed/Refractory, Indolent or Aggressive Lymphoma

AU - Linton, Kim

AU - Dreyling, Martin

AU - Morschhauser, Franck

AU - Bron, Dominique

AU - Bouabdallah, Krimo

AU - Vitolo, Umberto

AU - Neste, Eric Van den

AU - Mappa, Silvia

AU - Giurescu, Marius

AU - Childs, Barrett H.

AU - Zinzani, Pier Luigi

PY - 2013/12

Y1 - 2013/12

M3 - Poster

T2 - American Society of Hematology Annual Conference

Y2 - 1 January 1824

ER -